BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8015766)

  • 1. Tumor markers in epithelial ovarian cancer. Clinical applications.
    Hempling RE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor markers in the monitoring of ovarian cancer].
    Xu SX
    Zhonghua Fu Chan Ke Za Zhi; 1990 Nov; 25(6):345-7, 383. PubMed ID: 2282861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum lipid-associated sialic acid (LSA) in diagnosing and monitoring ovarian cancer].
    Yue K; Bian M; Zhu D; Liu W; Siu S
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1995 Apr; 17(2):128-32. PubMed ID: 7656393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lipid-associated sialic acid and serum CA 125 as indicators of disease status with advanced ovarian cancer.
    Vardi JR; Tadros GH; Foemmel R; Shebes M
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):379-83. PubMed ID: 2761915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of polyamine determination in monitoring malignant gynaecological tumours.
    Szarka G; Pulay T; Csömör S; Tran-Phuong-Mai ; Schumann B
    Acta Chir Hung; 1988; 29(4):365-72. PubMed ID: 3239336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma.
    Tseng PC; Sprance HE; Carcangiu ML; Chambers JT; Schwartz PE
    Obstet Gynecol; 1989 Sep; 74(3 Pt 1):384-7. PubMed ID: 2761916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor markers in epithelial ovarian cancer].
    Di Cocco B; Calabretta F; Alghisi F; Salesi N; Bossone G
    Minerva Ginecol; 2003 Aug; 55(4):327-32. PubMed ID: 14581857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of neopterin determination as a tumour marker in ovarian cancer.
    Szarka G; Pulay T; Csömör S; Tran-Phoung-Mai ; Schumann B
    Acta Chir Hung; 1988; 29(4):359-64. PubMed ID: 3239335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating mucins as tumor markers in ovarian cancer (review).
    Devine PL; McGuckin MA; Ward BG
    Anticancer Res; 1992; 12(3):709-17. PubMed ID: 1622128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical usefulness of tumor markers for the diagnosis of ovarian cancer].
    Ito K; Udagawa Y; Nozawa S
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1964-70. PubMed ID: 1417005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case control study of glycoprotein status in ovarian carcinoma.
    Aranganathan S; Senthil K; Nalini N
    Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.
    Baron AT; Cora EM; Lafky JM; Boardman CH; Buenafe MC; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):103-13. PubMed ID: 12582019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
    Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of CA-125 in epithelial ovarian cancer patients during and after chemotherapy.
    Lukácskó I; Hernádi Z; Sápy T; Borsos A
    Acta Chir Hung; 1997; 36(1-4):213-4. PubMed ID: 9408350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor markers: new prospects in the diagnosis and clinical monitoring of malignant epithelial neoplasms of the ovary].
    Gadducci A; Ferdeghini M; Prato B; Bartolini T; Nicolini A; Scatena P; Facchini V; Bianchi R; Fioretti P
    Ann Ostet Ginecol Med Perinat; 1985; 106(1):34-9. PubMed ID: 2994537
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer.
    No JH; Jeon YT; Kim YB; Song YS
    Gynecol Obstet Invest; 2011; 71(2):136-40. PubMed ID: 21160138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers in ovarian cancer.
    Kiricuta I; Bojan O; Munteanu S
    Arch Geschwulstforsch; 1986; 56(1):35-8. PubMed ID: 3964031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
    Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
    Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of markers may prove useful in screening for ovarian CA.
    Oncology (Williston Park); 1994 Jun; 8(6):79-80. PubMed ID: 8074986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.